Ariel Miller

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. ncbi request reprint Vitamin B12, demyelination, remyelination and repair in multiple sclerosis
    Ariel Miller
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa 34362, Israel
    J Neurol Sci 233:93-7. 2005
  2. pmc Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells
    Noa Henig
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    PLoS ONE 8:e62366. 2013
  3. pmc Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
    Iris Grossman
    IsraGene, Haifa, Israel Cabernet Pharmaceuticals, R David Thomas Center, One Science Drive, BOX 90344, Durham, NC 27708 USA
    EPMA J 1:317-27. 2010
  4. doi request reprint Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments
    Ariel Miller
    Technion Israel Institute of Technology, Carmel Medical Center, Department of Neurology, 7 Michal St, Haifa 34362, Israel
    Expert Rev Neurother 11:1077-88. 2011
  5. ncbi request reprint Translation towards personalized medicine in Multiple Sclerosis
    Ariel Miller
    Multiple Sclerosis and Brain Research Center, Carmel Medical Center, Israel
    J Neurol Sci 274:68-75. 2008
  6. ncbi request reprint Health-related quality of life in multiple sclerosis: psychometric analysis of inventories
    Ariel Miller
    Neuroimmunology Unit and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    Mult Scler 11:450-8. 2005
  7. ncbi request reprint Bio-markers of disease activity and response to therapy in multiple sclerosis
    Ariel Miller
    Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Institute for Research in the Medical Sciences, Faculty of Medicine, Technion Israel Institute of Technology, 7 Michal Street, Haifa 34362, Israel
    Clin Neurol Neurosurg 106:249-54. 2004
  8. ncbi request reprint Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
    Ariel Miller
    Center for Multiple Sclerosis, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Neurol Sci 259:67-73. 2007
  9. ncbi request reprint Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies
    Ariel Miller
    Center for Multiple Sclerosis, Department of Neurology, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion, Haifa, Israel
    J Neurol Sci 245:153-9. 2006
  10. ncbi request reprint Multiple sclerosis: from basic immunopathology to immune intervention
    Ariel Miller
    Neuroimmunology Research Unit, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences and Faculty of Medicine, Technion Isreal Institute of Technology, Haifa 34362, Israel
    Clin Neurol Neurosurg 104:172-6. 2002

Collaborators

Detail Information

Publications59

  1. ncbi request reprint Vitamin B12, demyelination, remyelination and repair in multiple sclerosis
    Ariel Miller
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa 34362, Israel
    J Neurol Sci 233:93-7. 2005
    ....
  2. pmc Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells
    Noa Henig
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    PLoS ONE 8:e62366. 2013
    ..The aim of the present study was to identify novel, cell-specific IFN-β functions and pathways in tumor necrosis factor (TNF)-α-activated monocytes that may have been missed in studies using PBMCs...
  3. pmc Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics
    Iris Grossman
    IsraGene, Haifa, Israel Cabernet Pharmaceuticals, R David Thomas Center, One Science Drive, BOX 90344, Durham, NC 27708 USA
    EPMA J 1:317-27. 2010
    ..We conclude by discussing the relevance of pharmacogenetics and other biomarkers to the prediction, prevention and personalization of MS medications in the horizon...
  4. doi request reprint Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments
    Ariel Miller
    Technion Israel Institute of Technology, Carmel Medical Center, Department of Neurology, 7 Michal St, Haifa 34362, Israel
    Expert Rev Neurother 11:1077-88. 2011
    ..As life expectancy lengthens and the neurologic settings of PBA become more common, the need for treatment can be expected to increase...
  5. ncbi request reprint Translation towards personalized medicine in Multiple Sclerosis
    Ariel Miller
    Multiple Sclerosis and Brain Research Center, Carmel Medical Center, Israel
    J Neurol Sci 274:68-75. 2008
    ..In light of the rapid advances in technology and progress in applying individualized treatment strategies in other diseases, 'Personalized Medicine' for MS seems feasible within the coming years...
  6. ncbi request reprint Health-related quality of life in multiple sclerosis: psychometric analysis of inventories
    Ariel Miller
    Neuroimmunology Unit and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    Mult Scler 11:450-8. 2005
    ..The aim was to gain insight into HRQoL as viewed by Israeli multiple sclerosis (MS) patients, with an eye to its cross-cultural applicability, using psychometric analysis and a regression-based procedure...
  7. ncbi request reprint Bio-markers of disease activity and response to therapy in multiple sclerosis
    Ariel Miller
    Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Institute for Research in the Medical Sciences, Faculty of Medicine, Technion Israel Institute of Technology, 7 Michal Street, Haifa 34362, Israel
    Clin Neurol Neurosurg 106:249-54. 2004
  8. ncbi request reprint Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
    Ariel Miller
    Center for Multiple Sclerosis, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Neurol Sci 259:67-73. 2007
    ..In addition, clinical studies pertaining to the safety and efficacy of DM/Q in a variety of neurological disease states are ongoing...
  9. ncbi request reprint Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies
    Ariel Miller
    Center for Multiple Sclerosis, Department of Neurology, Carmel Medical Center, Rappaport Faculty of Medicine and Research Institute, Technion, Haifa, Israel
    J Neurol Sci 245:153-9. 2006
    ..When administered in a fixed combination with quinidine, dextromethorphan is effective in treating PBA in patients with ALS, and preliminary results suggest that this therapy also is effective in treating MS-related PBA...
  10. ncbi request reprint Multiple sclerosis: from basic immunopathology to immune intervention
    Ariel Miller
    Neuroimmunology Research Unit, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences and Faculty of Medicine, Technion Isreal Institute of Technology, Haifa 34362, Israel
    Clin Neurol Neurosurg 104:172-6. 2002
  11. ncbi request reprint Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status
    Ariel Miller
    Multiple Sclerosis Center, Carmel Medical Center, Technion Israel Institute of Technology, Haifa, Israel
    Qual Life Res 15:259-71. 2006
    ....
  12. doi request reprint Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse
    Eli Somer
    Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
    Mult Scler 16:463-71. 2010
    ..Further research should explore whether the employment of specific ways of coping can reduce the risk for relapse among patients with multiple sclerosis during periods of distress...
  13. doi request reprint Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis
    Dana Haves-Zburof
    Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Cell Mol Med 15:2421-9. 2011
    ....
  14. ncbi request reprint Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells
    Tamir Ben-Hur
    Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    J Neuroimmunol 175:12-8. 2006
    ..IFN-beta, on the other hand, appears to have an anti-proteolytic influence that may attenuate such NPC-mediated repair processes...
  15. ncbi request reprint Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis
    Yanina Galboiz
    Neuroimmunology Unit, Department of Neurology, Carmel Medical Center, 7 Michal Street, Haifa, Israel
    J Neuroimmunol 131:191-200. 2002
    ....
  16. doi request reprint The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis
    Daniel Golan
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    Brain Behav Immun 32:180-5. 2013
    ..Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS. We hypothesized that vitamin D and melatonin may have related influences in patients with MS...
  17. doi request reprint Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel
    Michal Siegel
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Israel
    Mult Scler 18:1737-44. 2012
    ..Multiple sclerosis (MS) prevalence and genetic susceptibility varies among the different ethnic groups of Jews and Arabs in Israel...
  18. ncbi request reprint Auditory feedback control for improvement of gait in patients with Multiple Sclerosis
    Yoram Baram
    Department of Computer Science, Technion Israel Institute of Technology, Haifa, Israel
    J Neurol Sci 254:90-4. 2007
    ..To study the use of auditory feedback for gait management and rehabilitation in patients with Multiple Sclerosis (MS)...
  19. doi request reprint Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect
    Guy Haiman
    Department of Neurology, Carmel Medical Center, Technion Israel Institute of Technology, Haifa, Israel
    J Clin Psychopharmacol 29:444-52. 2009
    ..In conclusion, differences in brain activity were observed before and after medication. Also, DM/Q administration resulted in normalization of behavioral and electrophysiological measures...
  20. ncbi request reprint Immunological indicators of disease activity and prognosis in multiple sclerosis
    Yanina Galboiz
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Rappaport Institute for Research in the Medical Sciences, Technion Israel Institute of Technology, 7 Michal Street, Haifa 34362, Israel
    Curr Opin Neurol 15:233-7. 2002
    ..Recent studies focusing on the identification of possible immunological markers in multiple sclerosis will be reviewed...
  21. ncbi request reprint The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta
    Sarah Shapiro
    Immunology Research Unit, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel
    J Neuroimmunol 144:116-24. 2003
    ..These results confirm IFN-mediated modulation of the APC surface within the immunological-synapse and implicate CD80 and CD86 as targets for interventional therapies in MS as well as other Th1-mediated autoimmune diseases...
  22. ncbi request reprint Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis
    Doron Melamed
    Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Int Immunol 18:1355-62. 2006
    ..We conclude that B lymphocyte development is accompanied with MMP-9 secretion and the developing cells are competent to modify this secretion upon different immune stimuli...
  23. ncbi request reprint The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells
    Michal Abraham
    Neuroimmunology and Immunology Research Units, Carmel Medical Center, and Rappaport Institute for Research in the Medical Sciences, and Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Int Immunol 14:1449-57. 2002
    ....
  24. doi request reprint The ubiquitin-proteasome pathway regulates claudin 5 degradation
    Ilana Mandel
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Cell Biochem 113:2415-23. 2012
    ....
  25. doi request reprint Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses
    Lea Glass-Marmor
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Neuroimmunol 210:124-7. 2009
    ..These findings provide preliminary characterization of biomarkers in the application of chronobiology-based glucocorticoid therapeutics in MS and other immune disorders...
  26. ncbi request reprint Hypoxia of endothelial cells leads to MMP-2-dependent survival and death
    Yaara Ben-Yosef
    Immunology Research Unit, Carmel Medical Center, 7 Michal St, Haifa 34362, Israel
    Am J Physiol Cell Physiol 289:C1321-31. 2005
    ..Hence, in the hypoxic microenvironment, MMP-2 appears to have a dual autocrine role in determining the fate of ECs...
  27. ncbi request reprint Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis
    Sarah Shapiro
    Immunology Research Unit, Lady Davis Carmel Medical Center, 7 Michal Street, Haifa, 34362 Israel
    J Neurol Sci 206:43-8. 2003
    ....
  28. doi request reprint Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-β and role played in cell migration
    Elsebeth Staun-Ram
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Neuroimmunol 232:200-6. 2011
    ..These findings support further studies in the importance of Cathepsins and Cystatins in immunomodulation...
  29. ncbi request reprint Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis
    Elias Toubi
    Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 31096 Haifa, Israel
    J Neuroimmunol 251:45-54. 2012
    ..These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially other immune-mediated diseases...
  30. ncbi request reprint Tight junction proteins expression and modulation in immune cells and multiple sclerosis
    Ilana Mandel
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    J Cell Mol Med 16:765-75. 2012
    ....
  31. doi request reprint Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis
    Lena Melamud
    Division of Neuroimmunology and Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel
    J Neurol Sci 314:37-40. 2012
    ..The role of melatonin in MS-related sleep disturbances and fatigue as well as the interaction between melatonin and Interferon beta (IFN-β) treatment were the subject of this study...
  32. ncbi request reprint Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
    Iris Grossman
    Division of Neuroimmunology and Multiple Sclerosis Center, Rappaport Faculty of Medicine and Research Institute, Technion and Carmel Medical Center, Haifa, Israel
    Pharmacogenet Genomics 17:657-66. 2007
    ..These findings provide additional progress toward development of pharmacogenetics-based personalized treatment for multiple sclerosis...
  33. ncbi request reprint Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells
    Michal Abraham
    Neuroimmunology Research Unit, Carmel Medical Center, Haifa, Israel
    J Neuroimmunol 163:157-64. 2005
    ....
  34. doi request reprint Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect
    Guy Haiman
    Multiple Sclerosis and Brain Research Czenter, Department of Neurology, Carmel Medical Center, Haifa, Israel
    J Neurol Sci 271:137-47. 2008
    ..To characterize the brain activity and associated cortical structures involved in pseudobulbar affect (PBA), a condition characterized by uncontrollable episodes of emotional lability in patients with multiple sclerosis (MS)...
  35. ncbi request reprint Gene expression profiling of the response to interferon Beta in epstein-barr-transformed and primary B cells of patients with multiple sclerosis
    Rana Khsheibun
    Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    PLoS ONE 9:e102331. 2014
    ..The usage of LCLs from patient-based repositories may facilitate future studies of drug response in MS and other immune-mediated disorders with a B cell component. ..
  36. doi request reprint T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2
    Eyal Ben-Ami
    Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Autoimmun Rev 13:187-96. 2014
    ....
  37. doi request reprint Telemedicine for multiple sclerosis patients: assessment using Health Value Compass
    Keren Zissman
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    Mult Scler 18:472-80. 2012
    ..Telemedicine carries the potential of improving accessibility to health services, especially for disabled people...
  38. pmc Chronotherapy using corticosteroids for multiple sclerosis relapses
    Lea Glass-Marmor
    Division of Neuroimmunology, Multiple Sclerosis Center, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel
    J Neurol Neurosurg Psychiatry 78:886-8. 2007
    ..In diseases characterised by aberrant immune activity, chronotherapy (a treatment regimen tailored to diurnal body rhythms) may increase the efficiency, safety and tolerability of drugs...
  39. ncbi request reprint Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback
    Yoram Baram
    Department of Computer Science, Technion Israel Institute of Technology, Technion City, Haifa, Israel
    Disabil Rehabil Assist Technol 5:323-6. 2010
    ....
  40. pmc Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes
    Radu Ionescu
    Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion, Israel Institute of Technology, Haifa 32000, Israel
    ACS Chem Neurosci 2:687-93. 2011
    ..The results could serve also as a launching pad for the discrimination between different subphases or stages of multiple sclerosis as well as for the identification of multiple sclerosis patients who would respond well to immunotherapy...
  41. doi request reprint Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis
    Ilana Mandel
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Carmel Medical Center, Haifa, Israel
    J Neuroimmunol 244:51-6. 2012
    ..Concomitantly, the expression levels of the pro-apoptotic protein BAK were decreased in MS patients at relapse. These findings suggest the dysregulation of the apoptosis-related proteins MCL1 and BAK in MS...
  42. ncbi request reprint Cognitive strategies application of multiple sclerosis patients
    Smadar Birnboim
    The Center of Multiple Sclerosis and Brain Research, Carmel Medical Center, Haifa, Israel
    Mult Scler 10:67-73. 2004
    ....
  43. ncbi request reprint Impact of exposure to war stress on exacerbations of multiple sclerosis
    Daniel Golan
    Multiple Sclerosis Center and Department of Neurology, Carmel Medical Center, Haifa, Israel
    Ann Neurol 64:143-8. 2008
    ..To assess the relation between stress caused by the perils of rocket attack on civilian centers in northern Israel during the 2006 war between Hezbollah and Israel and multiple sclerosis (MS) exacerbations...
  44. pmc Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare
    Izabella Lejbkowicz
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, P O Box 9649, Haifa 31096, Israel
    Mult Scler Int 2010:640749. 2010
    ..This paper suggests that MS patients benefit from online information, and it emphasizes the importance of resources tailored to patients needs...
  45. doi request reprint Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis
    Izabella Lejbkowicz
    Pharmacogenetics and Translational Genetics Center, Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    Expert Rev Neurother 12:343-52. 2012
    ....
  46. ncbi request reprint Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells
    Nitza Lahat
    Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    J Neuroimmunol 132:123-8. 2002
    ..These results demonstrate a possible new mechanism by which Pb may induce neuropathological processes...
  47. ncbi request reprint Neuroimmunology in Israel--2002: proceedings of the 2nd annual meeting of the Israel society of neuroimmunology
    Dimitrios Karussis
    Department of Neurology, Hadassah Medical Center, Jerusalem, Israel
    J Neuroimmunol 131:1-4. 2002
  48. ncbi request reprint Virtual reality cues for improvement of gait in patients with multiple sclerosis
    Yoram Baram
    Department of Computer Science, Technion Israel Institute of Technology, Haifa, Israel
    Neurology 66:178-81. 2006
    ..To study the effects of visual cues, provided through a portable visual-feedback virtual reality (VR) apparatus, on the walking abilities of patients with multiple sclerosis (MS)...
  49. ncbi request reprint Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease
    Michael Inspector
    Neuroimmunology Unit, Carmel Medical Center, Haifa, Israel
    Eur Neurol 53:155-7. 2005
  50. ncbi request reprint Emotional responses of children and adolescents to parents with multiple sclerosis
    Rivka Yahav
    Faculty of Social Welfare and Health Studies, School of Social Work, University of Haifa, Haifa, Israel
    Mult Scler 11:464-8. 2005
    ..We consider the interaction between the sex of the parent and the sex of the child in connection with these feelings and discuss the implications of the 'parental child' role of these children...
  51. doi request reprint Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases
    Eyal Ben-Ami
    Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Autoimmun Rev 10:410-5. 2011
    ....
  52. ncbi request reprint Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing
    Ilan Gruenwald
    Neuro urology unit, Rambam Medical Center, Haifa, Israel
    Mult Scler 13:95-105. 2007
    ..Quantitative sensory testing (QST) has recently been used to assess normal neural function of the female genitalia. In this study we used QST for assessment of the genital neural function of female MS patients...
  53. ncbi request reprint Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis
    Hillel S Panitch
    Neurology Health Care Service, Fletcher Allen Health Care, University of Vermont, Burlington, 05401, USA
    Ann Neurol 59:780-7. 2006
    ....
  54. ncbi request reprint Emerging therapeutic targets in multiple sclerosis
    Paulo Fontoura
    Department of Immunology, Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal
    Curr Opin Neurol 19:260-6. 2006
    ..The aim of this review is to describe the recent findings regarding the pathogenesis of multiple sclerosis and their translation to new therapies...
  55. ncbi request reprint Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis
    Mikael Schwarz
    Glycominds Ltd, Lod 71291, Israel
    J Neurol Sci 244:59-68. 2006
    ..0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management...
  56. doi request reprint Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial
    F Fazekas
    Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
    Neurology 71:265-71. 2008
    ..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety...
  57. ncbi request reprint Multiple sclerosis frequency in Israel's diverse populations
    Milton Alter
    Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA
    Neurology 66:1061-6. 2006
    ....
  58. pmc In vitro induction of regulatory T cells by anti-CD3 antibody in humans
    Michal Abraham
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    J Autoimmun 30:21-8. 2008
    ..Thus, we have identified human T cells with strong in vitro regulatory properties induced in vitro by anti-CD3 which appear to act in a non-HLA restricted fashion by affecting antigen presenting cells...
  59. ncbi request reprint Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA 94121, USA Email
    Curr Med Res Opin 23:2823-32. 2007
    ....